ReviewAmerican journal of preventive cardiology2020
Cardiovascular risk assessment: The foundation of preventive cardiology.
Review in American journal of preventive cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Characteristics of Cardiovascular Disease Prediction Models Considering Mental Disorders: A Systematic Review.Journal of the American Heart Association · 2026Pooled it
- Cardiovascular disease risk prediction models in the Chinese population- a systematic review and meta-analysis.BMC public health · 2022Pooled it
- Alzheimer's disease-like brain pattern biomarker: capturing risks and predicting disease onset.Molecular psychiatry · 2026Article
- Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration Study.Journal of the American Heart Association · 2026Observational
- Association of PM2.5 exposure with 10-year atherosclerotic cardiovascular disease risk: a mediation analysis of blood and urinary biomarkers.Frontiers in public health · 2026Article
- Alzheimer's Disease-Like Brain Pattern Biomarker: Capturing Risks and Predicting Disease Onset.Research square · 2025Article
- Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications.Diabetes, obesity & metabolism · 2025Review
- A Proposed Framework to Aid Primary Care Clinicians in Promoting Cardiovascular Health.Journal of general internal medicine · 2025Article
- Frailty Markers and Falls Among US Clergy.Journal of religion and health · 2025Article
- Cardiovascular disease risk prediction by Framingham risk score in women with polycystic ovary syndrome.Reproductive biology and endocrinology : RB&E · 2025Article
- Incorporating longitudinal history of risk factors into atherosclerotic cardiovascular disease risk prediction using deep learning.Scientific reports · 2024Article
- Fasting mimicking diet cycles versus a Mediterranean diet and cardiometabolic risk in overweight and obese hypertensive subjects: a randomized clinical trial.npj metabolic health and disease · 2023Article
- Oral health and 10-year cardiovascular risk in US adults: mediating role of inflammatory diet and vitamin D.Clinical oral investigations · 2023Article
- Cardiovascular disease risk evaluation impact in patients with rheumatoid arthritis.American journal of preventive cardiology · 2022Article
- Review
- Hypertension as a risk factor for atherosclerosis: Cardiovascular risk assessment.Frontiers in cardiovascular medicine · 2022Review
- Optimization of time interval for the measurement of plasma lipids for cardiovascular disease risk assessment.Expert review of molecular diagnosticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The foundation of preventive cardiology begins with knowing the patient's baseline cardiovascular disease (CVD) risk from which the patient-clinician risk discussion informs on the best ways to lower risk through lifestyle management, as well as a decision about the initiation and intensity of pharmacologic therapy. Global CVD risk assessment involves estimation of cardiovascular risk using a basic panel of risk factors. The Framingham Heart Study championed the first such risk scores, followed by others around the world. Most recently, the Pooled Cohort Equations (PCE) have been recommended in the United States as a starting point in CVD risk assessment. Persons at low (<5%) 10-year risk are generally recommended for lifestyle management only and those at highest (>20%) 10-year risk are recommended for both lifestyle and pharmacologic therapy to reduce risk. Assessing the presence of one or more "risk enhancing" factors is intended to inform the treatment decision in those at borderline (5-<7.5%) or intermediate (7.5-20%) risk, with the use of coronary calcium scores to further refine the treatment decision. Moreover, not all those with ASCVD are treated equal, and recent guidelines provide criteria for identifying those at very high risk. While current techniques best predict long-term risk of CVD events, biomarkers strategies are being developed to predict near-term events, and other imaging techniques such as coronary CT angiography and vascular MRI hold promise to identify vulnerable plaque. Validation and incorporating into clinical practice such state of the art techniques will be vital to moving CVD risk assessment to the next level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.